Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M. Younossi, Victor Ankoma‐Sey, Philip N. Newsome et al.|The Lancet|2019Cited by 1.2k
Real-world data reveal a diagnostic gap in non-alcoholic fatty liver diseaseM Alexander, William Alazawi|BMC Medicine|2018Cited by 272
A global action agenda for turning the tide on fatty liver diseaseJeffrey V. Lazarus, Henry E. Mark, Alina M. Allen et al.|Hepatology|2023Cited by 90
(untitled)Stuart McPherson, William Alazawi, Matthew J. Armstrong et al.|Discovery Research Portal (University of Dundee)|2022Cited by 62
An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical PracticeLuis Antonio Diaz, Rohit Loomba, Veeral Ajmera et al.|Clinical Gastroenterology and Hepatology|2025Cited by 16